ornidazole
Small moleculeexperimental
Ornidazole is an antibiotic used to treat protozoan infections. A synthetic nitroimidazole, it is commercially obtained from an acid-catalyzed reaction between 2-methyl-5-nitroimidazole and epichlorohydrin. Ornidazole is nothing but chloro-secnidazole. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started May 1, 2016 (NCT02618720)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetOTHER
Produces reactive intermediates
Mechanism not fully elucidated.
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ncc([N+](=O)[O-])n1CC(O)CCl- Mol. weight
- 219.63 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOrnidazole ↗
- ChEMBLCHEMBL1449676 ↗
Also known as
- ornidal
- ornidazole
- ornidazole
- ornidazole
- ornidazole
- ornidazole
- ornidazole
- ornidazole
- ornidazole
- ornidone
- ornilox
- ornisid
- ornitop
- ro-70207
- ro-70207
- tiberal
- tiberal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03475680 | Phase 3 | Jun 1, 2018 | Assistance Publique - Hôpitaux de Paris |
| NCT03491540 | Phase 3 | May 1, 2018 | Assistance Publique - Hôpitaux de Paris |
| NCT02618720 | Phase 3 | May 1, 2016 | University Clermont Auvergne |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 2 | 2 | 1 | 2018 |
| University Clermont Auvergne | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1